SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Liebman who wrote (4116)2/18/1998 11:31:00 AM
From: Rocketman   of 9719
 
And only five years after it was an idea, of course back in '92-93 before the IPO, everyone said it couldn't be done on a non-exclusive basis and HGSI was the genomics darling, while INCY could barely get the time of day. And, the real winners are the VCs and the IPO investors who got in at $3.75 (split adjusted) and under. If you look at the INCY growth and profit picture and think about how much of any additional subscribers fees fall to the bottom line, and then think about the 6000+ royalty bearing intellectual property licenses they have issued, and then compare INCY to the rest of the biotech industry......they look damn hot. What cracks me up are people who don't understand biotech and the growth rates, who start saying how high INCY's PE ratio is, of course, most of the biotech industry has a negative PE ratio and no where near the guaranteed revenue stream. Full Stream Ahead!!!!

Rman
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News